Transforming the treatment of aortic regurgitation
JenaValve is redefining what it means to treat patients with severe aortic regurgitation.
Data presented from the ALIGN-AR Trial
Learn More
Innovations in TAVR:
The JenaValve Trilogy System
Learn More
About Us
JenaValve is a global medical device company
dedicated to supporting physicians
addresses the needs of patients with structural heart disease.
Upcoming Events
View All
PCR London Valves in London, UK
The Heart Team Course – focus on transcatheter therapies for valvular heart disease #PCRLV
PCR Imaging Valves in Madrid, ES
Imaging for any healthcare practitioner diagnosing, treating and monitoring patients with heart valve disease
Get in touch today to learn more about JenaValve and the Trilogy System
*Indications: The JenaValve Trilogy Heart Valve System is indicated for use in patients with native symptomatic, severe aortic regurgitation (AR) or symptomatic, severe aortic stenosis (AS), who are judged by a Heart Team (including a cardiac surgeon), to be at high or greater risk for surgical aortic valve replacement (AVR), with an STS score ≥ 8% at 30 days, or other comorbidities (e.g., porcelain aorta, frailty, chest wall irradiation) that are not captured by the STS risk calculator.
Contraindications: The JenaValve Trilogy Heart Valve System is contraindicated for use in patients who have known hypersensitivity or contraindication to Nitinol (titanium and/or nickel), an anti-coagulation/anti-platelet regimen or contrast medium that cannot be managed with premedication, or who have active bacterial endocarditis or other active infections.
US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.